A GPCR startup out of France and Canada scores its Series A after 20 years of wheeling and dealing

Having already nailed down multiple licensing and collaboration deals with Big Pharma giants like Bristol Myers Squibb and Pfizer, a France- and Quebec-based GPCR biotech now has its first VC financing round under its belt.

The I/O focused biotech Domain Therapeutics closed a Series A worth $42 million, the company...

Click to view original post